RNAseq transcriptomic profile of glioblastoma stem-like cells derived from U87MG cell line treated with a selective A3 adenosine receptor antagonist (MRS1220) under hypoxia

Glioblastoma Multiforme (GBM) is the primary brain tumor with the highest incident and mortality rates worldwide. This is because therapies are not effective, mainly due to tumor recurrence after surgical resection and chemotherapeutic treatment. Recurrence is mainly produced by a tumoral cell sub-population called Glioblastoma Stem-like Cells (GSCs), which are primarily responsible for chemo-resistance and tumor infiltration. We previously showed that in this sub-population, adenosine regulates chemo-resistance through its A3AR. The importance of this study lies in the confirmation that the adenosine/A3AR axis is a plausible therapeutic target to attack different features of GBM, including chemo-resistance and cell migration/invasion of GSCs. Total RNA isolated from U87MG-GSCs treated with vehicle (DMSO) and MRS1220 (10 µM) under hypoxia was analysed by RNA-seq using the high-throughput sequencing system HiSeq2500 (Illumina). Two paired-end RNAseq analyses were performed. In the first sequencing analysis, the equipment only released the reverse reads; these reads are the "single" files. With the same samples (the same libraries), the sequencing was repeated, obtaining both reads -- reverse and forward; these reads are the "pair" files. The counts obtained in the single and paired-end analyses were added and used for the determination of differential expression.